CJC-1295 without DAC

CJC-1295 (No DAC), also referred to as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). Specifically, it features modifications at four key amino acid positions designed to enhance chemical stability and confer resistance to rapid enzymatic degradation. cjc1295

In contrast to the DAC (Drug Affinity Complex) variant, this formulation lacks the lysine-biotin linker required for serum albumin binding. Consequently, it exhibits a shorter half-life that results in sharp, physiologically mimetic pulses of growth hormone release. cjc1295

Mechanistically, research has examined its capacity to stimulate robust, short-duration GH pulses directly from pituitary somatotroph cells. In addition, studies have investigated the downstream physiological effects of this pulsatile release on IGF-1 production, lean tissue accretion, lipid metabolism, and cellular repair processes. Furthermore, when evaluated alongside a growth hormone-releasing peptide (GHRP) such as Ipamorelin, research reveals pronounced synergistic effects driven by the simultaneous engagement of complementary receptor pathways. Overall, CJC-1295 (No DAC) serves as a principal research compound for investigating hypothalamic-pituitary somatotropic axis dynamics and metabolic regulation.